ArticlemBio2022
Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Surveillance of antibiotic-resistant bacteria integrating whole genome sequencing and epidemiological information - a global, systematic review, 2012-2023.Antimicrobial resistance and infection control · 2026Pooled it
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- AI-assisted MALDI-TOF MS for identifying carbapenem resistance in clinicalEmerging microbes & infections · 2026Article
- Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026Review
- The Novel Carbapenem, JDB/PQ-1-219, Has Potent Broad Spectrum Activity against Multi-Drug ResistantACS infectious diseases · 2026Article
- Comprehensive identification of sequence types belonging toMicrobial genomics · 2026Article
- Integrated clinical and genomic characterization ofJournal of medical microbiology · 2026Article
- Changes in Susceptibility Profiles ofJournal of clinical medicine · 2026Article
- Genomic signatures of dominant clones and evolutionary divergence ofMicrobial genomics · 2026Article
- Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- A Performance Evaluation of the VitekAntibiotics (Basel, Switzerland) · 2026Article
- Comparative genomic surveillance of carbapenem-resistantMicrobiology spectrum · 2026Article
- The therapeutic potential of phage pT2784 against ST40-KL47 typeMicrobiology spectrum · 2026Article
- ConfrontingInfection and drug resistance · 2026Review
- Comparative genomics of carbapenem resistant and susceptible clinicalFrontiers in cellular and infection microbiology · 2026Article
- The evolution of the multidrug-resistant and globally distributed ST2 Acinetobacter baumannii in China.BMC microbiology · 2025Article
- Article
- Carbapenem-ResistantMicroorganisms · 2025Review
- Review
- Contribution of RND superfamily multidrug efflux pumps AdeABC, AdeFGH, and AdeIJK to antimicrobial resistance and virulence factors in multidrug-resistantAntimicrobial agents and chemotherapy · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 12 institutions in 2 countries.
Alina IovlevaDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-3599-7221
Mustapha M MustaphaDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Marissa P GriffithDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Lauren KomarowThe Biostatistics Center, The George Washington University, Rockville, Maryland, USA.
Courtney LuterbachDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, North Carolina, USA.
Daniel R EvansDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Eric CoberDepartment of Infectious Diseases, Cleveland Clinicgrid.239578.2, Cleveland, Ohio, USA.
Sandra S RichterDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
Kirsten RydellDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Cesar A AriasDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Jesse T JacobDivision of Infectious Diseases, Department of Medicine, Emory Universitygrid.189967.8 School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0001-9811-6260
Robert A SalataDivision of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Michael J SatlinDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Darren WongDivision of Infectious Diseases, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Robert A BonomoDivision of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4784-3227
Vaughn S CooperDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-7726-0765
Daria Van TyneDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-7284-0103
Yohei DoiDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-9620-2525
University of Pittsburgh · USHouston Methodist · USUniversity of North Carolina at Chapel Hill · USCleveland Clinic · USCornell University · USEmory University · USFujita Health University · JPGeorge Washington University · USJacksonville College · USLouis Stokes Cleveland VA Medical Center · USUniversity of Southern California · USUniversity School · US
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MProject 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2025
$12.0MPredicting the emergence of antibiotic resistance through multi-omics approaches and Immune System-surveillanU01AI124302 · NIAID · BOSTON COLLEGE · PI BENTO, JOSE, COOPER, VAUGHN · 2016 to 2020
$10.2MUNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MColistin-resistant Acinetobacter baumanniiR01AI104895 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI, ERNST, ROBERT K · 2014 to 2024
$4.2MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MMolecular Mechanisms Of Daptomycin Resistance In EnterococciR01AI093749 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2011 to 2015
$1.9MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MStudy Network of Acinetobacter as a Carbapenem-Resistant Pathogen (SNAP)R21AI135522 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2018 to 2019
$460kMechanisms of cefiderocol resistanceR21AI151362 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2020 to 2021
$420kNIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI093749NIAID NIH HHS R01 AI104895NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS R21 AI135522NIAID NIH HHS R21 AI151362NIAID NIH HHS U01 AI124302NIAID NIH HHS UM1 AI104681NIGMS NIH HHS T32 GM086330NIH HHS R00EY02822NIH HHS R01AI072219NIH HHS R01AI14834201NIH HHS R21AI135522NIH HHS T32GM086330NIH HHS U01AI124302Wellcome Trust
Abstract
Carbapenem-resistant Acinetobacter baumannii (CR
Indexed as
Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsColistinDrug Resistance, BacterialHospitalsHumansInterleukin-1 Receptor-Like 1 ProteinMicrobial Sensitivity TestsUnited StatesAnti-Bacterial Agentsbeta-LactamasesCarbapenemsColistinInterleukin-1 Receptor-Like 1 ProteinAcinetobacter baumanniicarbapenem resistanceclinical epidemiologymolecular epidemiology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.